• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.大鼠肠道微生物对SN-38葡糖醛酸苷的快速去结合作用及对释放出的游离SN-38的吸附作用。
Oncol Lett. 2012 Mar;3(3):520-524. doi: 10.3892/ol.2011.519. Epub 2011 Dec 9.
2
Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.大鼠肠道微生物群对伊立替康及其活性代谢物SN-38的代谢
Oncol Rep. 2008 Oct;20(4):727-30.
3
Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.链霉素通过非抑制肠道腔β-葡萄糖醛酸酶活性的机制缓解伊立替康所致迟发性腹泻。
Cancer Chemother Pharmacol. 2011 Jan;67(1):201-13. doi: 10.1007/s00280-010-1310-4. Epub 2010 Mar 31.
4
Transporter and metabolic enzyme-mediated intra-enteric circulation of SN-38, an active metabolite of irinotecan: A new concept.经肠内转运体和代谢酶介导的伊立替康活性代谢物 SN-38 的肠内循环:新概念。
Biochem Biophys Res Commun. 2023 Jul 12;665:19-25. doi: 10.1016/j.bbrc.2023.04.109. Epub 2023 Apr 28.
5
Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.抑制肠道微生物群的β-葡萄糖醛酸酶可改变抗肿瘤药物盐酸伊立替康(CPT-11)活性代谢产物在大鼠体内的分布。
Cancer Chemother Pharmacol. 1998;42(4):280-6. doi: 10.1007/s002800050818.
6
Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.内源性生成的代谢物的局部酶促水解可增强CPT - 11的抗癌疗效。
Mol Cancer Ther. 2009 Apr;8(4):940-6. doi: 10.1158/1535-7163.MCT-08-0812.
7
Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.联合使用沙利度胺降低伊立替康毒性的药代动力学机制。
Curr Drug Metab. 2006 May;7(4):431-55. doi: 10.2174/138920006776873517.
8
Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.通过大肠杆菌定向β-葡萄糖醛酸酶疗法增强CPT-11抗癌活性的障碍。
PLoS One. 2015 Feb 17;10(2):e0118028. doi: 10.1371/journal.pone.0118028. eCollection 2015.
9
Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.结直肠癌患者及野生型UGT1A1基因患者中SN-38葡萄糖醛酸苷与SN-38的血浆浓度比值与中性粒细胞减少诱导之间的相关性。
Oncol Lett. 2012 Mar;3(3):694-698. doi: 10.3892/ol.2011.533. Epub 2011 Dec 22.
10
[Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].[评估总胆红素或SN-38/SN-38G比值作为伊立替康严重毒性预测指标的研究]
Gan To Kagaku Ryoho. 2009 Sep;36(9):1505-9.

引用本文的文献

1
Comparative Analysis of Gut Microbiota Responses to New SN-38 Derivatives, Irinotecan, and FOLFOX in Mice Bearing Colorectal Cancer Patient-Derived Xenografts.携带结直肠癌患者来源异种移植瘤的小鼠肠道微生物群对新型SN-38衍生物、伊立替康和FOLFOX反应的比较分析
Cancers (Basel). 2025 Jul 7;17(13):2263. doi: 10.3390/cancers17132263.
2
MiCK: a database of gut microbial genes linked with chemoresistance in cancer patients.MiCK:一个与癌症患者化疗耐药相关的肠道微生物基因数据库。
Database (Oxford). 2024 Dec 21;2024. doi: 10.1093/database/baae124.
3
Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era.精准医学时代人类肠道微生物群与药物相互作用的机制及临床意义
Biomedicines. 2024 Jan 16;12(1):194. doi: 10.3390/biomedicines12010194.
4
GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy.具有iRGD的谷胱甘肽响应性负载SN38二聚体的形状可转变纳米颗粒用于增强化学-光动力疗法
Acta Pharm Sin B. 2020 Dec;10(12):2348-2361. doi: 10.1016/j.apsb.2020.10.009. Epub 2020 Oct 15.
5
Irinotecan and Δ⁸-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers.伊立替康与Δ⁸-四氢大麻醇在大鼠肝脏中的相互作用:使用生化和遗传毒性标志物的初步评估。
Molecules. 2018 Jun 1;23(6):1332. doi: 10.3390/molecules23061332.
6
Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats.中药方剂生姜泻心汤对伊立替康诱导的大鼠迟发性腹泻的预防作用
Evid Based Complement Alternat Med. 2017;2017:7350251. doi: 10.1155/2017/7350251. Epub 2017 Jan 12.
7
Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.将基于知识的算法与两阶段筛选相结合,应用于接受伊立替康治疗患者的无假设基因组数据,以鉴定与不良反应相关的候选单核苷酸多态性。
PLoS One. 2014 Aug 15;9(8):e105160. doi: 10.1371/journal.pone.0105160. eCollection 2014.

本文引用的文献

1
Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.链霉素通过非抑制肠道腔β-葡萄糖醛酸酶活性的机制缓解伊立替康所致迟发性腹泻。
Cancer Chemother Pharmacol. 2011 Jan;67(1):201-13. doi: 10.1007/s00280-010-1310-4. Epub 2010 Mar 31.
2
Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.大鼠肠道微生物群对伊立替康及其活性代谢物SN-38的代谢
Oncol Rep. 2008 Oct;20(4):727-30.
3
Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity.喜树碱的细胞外和细胞内相互作用作为抗肿瘤活性决定因素的相关性。
Biochem Pharmacol. 2007 Nov 15;74(10):1437-44. doi: 10.1016/j.bcp.2007.04.027. Epub 2007 May 3.
4
Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.伊立替康吸附于口服吸附剂AST-120(可利迈仙)以预防迟发性腹泻。
Cancer Chemother Pharmacol. 2007 Feb;59(3):321-8. doi: 10.1007/s00280-006-0273-y. Epub 2006 Jun 13.
5
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.头孢克肟可使口服伊立替康实现更大剂量递增:一项针对难治性实体瘤儿科患者的I期研究。
J Clin Oncol. 2006 Feb 1;24(4):563-70. doi: 10.1200/JCO.2005.03.2847.
6
Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.针对抗肿瘤药物盐酸伊立替康(CPT-11)所致迟发性腹泻的最佳止泻治疗
Cancer Chemother Pharmacol. 2006 Oct;58(4):494-503. doi: 10.1007/s00280-006-0187-8. Epub 2006 Jan 25.
7
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.活性炭预防伊立替康所致腹泻的II期研究。
J Clin Oncol. 2004 Nov 1;22(21):4410-7. doi: 10.1200/JCO.2004.11.125.
8
New approaches to prevent intestinal toxicity of irinotecan-based regimens.预防基于伊立替康方案肠道毒性的新方法。
Cancer Treat Rev. 2004 Oct;30(6):555-62. doi: 10.1016/j.ctrv.2004.05.002.
9
Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.糖二酸1,4-内酯可预防大鼠CPT-11诱导的黏膜损伤。
J Cancer Res Clin Oncol. 2004 Jul;130(7):388-94. doi: 10.1007/s00432-004-0557-8.
10
Biliary excretion of irinotecan and its metabolites.伊立替康及其代谢产物的胆汁排泄。
J Pharm Pharm Sci. 2004 Jan 23;7(1):13-8.

大鼠肠道微生物对SN-38葡糖醛酸苷的快速去结合作用及对释放出的游离SN-38的吸附作用。

Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.

作者信息

Takakura Akira, Kurita Akinobu, Asahara Takashi, Yokoba Masanori, Yamamoto Michiko, Ryuge Shinichiro, Igawa Satoshi, Yasuzawa Yukitoshi, Sasaki Jiichiro, Kobayashi Hirosuke, Masuda Noriyuki

机构信息

Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374.

出版信息

Oncol Lett. 2012 Mar;3(3):520-524. doi: 10.3892/ol.2011.519. Epub 2011 Dec 9.

DOI:10.3892/ol.2011.519
PMID:22740943
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3362476/
Abstract

One of the dose-limiting toxicities of irinotecan hydrochloride (CPT-11) is delayed-onset diarrhea. CPT-11 is converted to its active metabolite, SN-38, which is conjugated to SN-38 glucuronide (SN-38G). SN-38G excreted in the intestinal lumen is extensively deconjugated by bacterial β-glucuronidase, resulting in the regeneration of SN-38, which causes diarrhea. However, the deconjugation of SN-38G by the intestinal microflora remains to be clarified. This study aimed to investigate the microbial transformation of SN-38G by an anaerobic mixed culture of rat cecal microorganisms. Concentrations of SN-38G and SN-38 were then determined using high-performance liquid chromatography. Complete deconjugation of SN-38G to SN-38 in the mixed cultures was observed within 1 h of incubation, with 62.7% of the added SN-38G being found in the supernatant. Approximately 80.4% of the SN-38 in the supernatant was bound to protein, and the remaining 19.6% was detected as active free SN-38. In total, only 12.3% (19.6 × 62.7%) of the SN-38G added to the test tube was found in the supernatant in the ultrafiltrable free form, indicating that approximately 90% of the SN-38G added to the growth medium either remained adsorbed onto the pelleted fraction or occurred in a protein-bound form in the supernatant. The remaining 10% of the SN-38G added to the growth medium existed in the unbound form, the form capable of causing damage to the intestinal membrane. In conclusion, these results indicated that the greater part of the SN-38 produced from SN-38G by the action of bacterial β-glucuronidase is rapidly adsorbed onto intestinal bacterial cell walls or dietary fibers in pelleted fraction, and only 10% remains in the ultrafiltrable unbound form in the intestinal luminal fluid.

摘要

盐酸伊立替康(CPT-11)的剂量限制性毒性之一是迟发性腹泻。CPT-11转化为其活性代谢产物SN-38,后者与SN-38葡糖醛酸苷(SN-38G)结合。排泄到肠腔中的SN-38G被细菌β-葡糖醛酸酶广泛地去结合,导致SN-38再生,进而引起腹泻。然而,肠道微生物群对SN-38G的去结合作用仍有待阐明。本研究旨在通过大鼠盲肠微生物的厌氧混合培养来研究SN-38G的微生物转化。然后使用高效液相色谱法测定SN-38G和SN-38的浓度。在混合培养物中,孵育1小时内观察到SN-38G完全去结合为SN-38,在上清液中发现62.7%的添加SN-38G。上清液中约80.4%的SN-38与蛋白质结合,其余19.6%被检测为活性游离SN-38。总体而言,添加到试管中的SN-38G仅有12.3%(19.6×62.7%)以可超滤的游离形式存在于上清液中,这表明添加到生长培养基中的SN-38G约90%要么仍吸附在沉淀部分,要么以上清液中蛋白质结合的形式存在。添加到生长培养基中的其余10%的SN-38G以未结合形式存在,这种形式能够对肠膜造成损伤。总之,这些结果表明,由细菌β-葡糖醛酸酶作用从SN-38G产生的SN-38的大部分迅速吸附到肠道细菌细胞壁或沉淀部分的膳食纤维上,只有10%以可超滤的未结合形式保留在肠腔液中。